Related Experiment Video
Updated: May 18, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Tools to therapeutically harness the human antibody response
Patrick C Wilson1, Sarah F Andrews
1Department of Medicine/Rheumatology, University of Chicago, Chicago, Illinois 60637, USA. wilsonp@uchicago.edu
Nature Reviews. Immunology
|September 26, 2012
Summary
Human antibody responses yield powerful therapeutic reagents. These natural antibodies, particularly against influenza and HIV, offer new targets for vaccines and immunotherapies.
Area of Science:
- Immunology and Virology
- Therapeutic Antibody Development
Background:
- Natural human antibody responses provide specific, neutralizing, and self-tolerant therapeutic reagents.
- Advances in isolating and characterizing monoclonal antibodies from natural infections or vaccinations are significant.
Purpose of the Study:
- To summarize technological tools for identifying and characterizing human monoclonal antibodies.
- To explore the application of these tools in combating infectious diseases, focusing on influenza and HIV.
Main Methods:
- Review of current technologies for human monoclonal antibody isolation and characterization.
- Analysis of studies focusing on antibody responses to influenza virus and Human Immunodeficiency Virus (HIV).
Main Results:
- Human antibody responses reveal critical epitopes for vaccine design.
- Monoclonal antibodies derived from natural responses are potential immunotherapeutic agents.
Conclusions:
- Technological advancements enable the discovery of potent human monoclonal antibodies.
- These antibodies hold promise for developing novel strategies against infectious diseases like influenza and HIV.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:36Humoral Immune Responses
Overview